Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study;Utilidad del NT-proBNP en el diagnóstico de la hipertrofia ventricular izquierda en el paciente hipertenso. Estudio mediante resonancia cardiaca

Revista Espanola de Cardiologia

Volumn 61, Issue 9, 2008, Pages 972-975

  Morillas Blasco, Pedro J ^a   Castillo, Jesús ^a   Quiles, Juan ^a   Nuñez, Daniel ^a   Guillén, Silvia ^a   Maceira, Alicia ^b   Rivera, Miguel ^c   Bertomeu, Vicente ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b Hospital General Universitario Avda   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Arterial hypertension; Cardiac magnetic resonance; Ventricular hypertrophy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEIVER OPERATING CHARACTERISTIC;

EID: 51949096589     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13125520     Document Type: Article

References (13)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-536.
2. Alfakih K, Reid S, Hall A, Sivananthan M. The assessment of left ventricular hypertrophy in hypertension. J Hypertens. 2006; 24:1223-30.
3. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Zanchetti A. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens. 2006;24:1671-7.
4. Almenar L, Martínez-Dolz L. Péptidos natriuréticos en insuficiencia cardiaca. Rev Esp Cardiol. 2006;6 Supl F:15-26.
5. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem. 2005;41:2245-51.
6. Vasan RS, Benjamín EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framinghan heart study. JAMA. 2002;288:1252-9.
7. Rivera JM, Talens-Visconti R, Salvador A, Bertomeu V, Miró V, Jordán A, et al. Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. Int J Cardiol. 2004;96:265-71.
8. Myerson SG, Bellenger NG, Pennell DJ. Assesment of left ventricular mass by cardiovascular magnetic resonance. Hypertension. 2002;39:750-5.
9. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:29-34.
10. Watzinger N, Maier R, Reiter U, Reiter G, Fuernau G, Wonisch M, et al. Clinical applications of cardiovascular magnetic resonance. Curr Pharm Des. 2005;11:457-75.
11. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417-26.
12. Kim SW, Park SW, Lim SH, Kwow SU, Choi YJ, Park MK, et al. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide levels in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol. 2006;29:155-60.
13. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation. 1981;63:1391-8.